M
Michael Parkinson
Researcher at Dublin City University
Publications - 19
Citations - 1183
Michael Parkinson is an academic researcher from Dublin City University. The author has contributed to research in topics: Fasciola hepatica & Fasciolosis. The author has an hindex of 14, co-authored 19 publications receiving 1138 citations. Previous affiliations of Michael Parkinson include St Patrick's College, Dublin.
Papers
More filters
Journal ArticleDOI
Prognostic importance of survivin in breast cancer
Susan Kennedy,Lorraine O'Driscoll,Rachel V. Purcell,N Fitz-simons,Enda W. McDermott,Arnold D.K. Hill,Niall O'Higgins,Michael Parkinson,R. Linehan,Martin Clynes +9 more
TL;DR: Results show that survivin is frequently overexpressed in primary breast cancer, and nuclear expression is most common and is an independent prognostic indicator of good prognosis.
Journal ArticleDOI
Immunodiagnosis of Fasciola hepatica infection (fascioliasis) in a human population in the Bolivian Altiplano using purified cathepsin L cysteine proteinase.
TL;DR: A standardized diagnostic test for human fascioliasis, based on an ELISA that detects IgG4 responses to CL1, could be available to all diagnostic centers if sufficient quantities of recombinant CL1 can be produced.
Journal ArticleDOI
Diagnosis of human fasciolosis in the Gilan province of Northern Iran: application of cathepsin L-ELISA.
TL;DR: In this paper, an enzyme linked immunosorbant assay (ELISA) test was developed for diagnosing human fasciolosis in an endemic area of northern Bolivia.
Journal ArticleDOI
Short report: Immunodiagnosis of human fascioliasis using recombinant Fasciola hepatica cathepsin L1 cysteine proteinase.
TL;DR: Recombinant CL1, generated by functional expression of the cDNA in Saccharomyces cerevisiae, is used in this immunodiagnostic test and shows excellent potential for the development of the first standardized assay for the sensitive and specific diagnosis of human fascioliasis.
Journal ArticleDOI
Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study.
Annemarie Larkin,Lorraine O'Driscoll,Susan Kennedy,Susan Kennedy,Rachel V. Purcell,Rachel V. Purcell,Elizabeth Moran,John Crown,Michael Parkinson,Martin Clynes +9 more
TL;DR: Assessment of MRP‐1 expression at diagnosis may offer useful prognostic information in subgroups of patients with stage 1 or stage 2 high‐grade tumours who receive CMF‐based adjuvant chemotherapy.